0 Commentaires
0 Parts
2KB Vue
0 Aperçu
Rechercher
Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis
-
Connectez-vous pour aimer, partager et commenter!
-
Emerging Trends Influencing the Antibody Drug Conjugates MarketAsia-Pacific is expected to witness rapid growth in the coming years due to increasing healthcare investments and expanding pharmaceutical manufacturing capabilities. Countries like China and India are emerging as important research hubs. The Antibody Drug Conjugates (ADC) market is projected to grow significantly, reaching US$38,077.45 million by 2031 from US$8,105.65 million in 2023,...0 Commentaires 0 Parts 4KB Vue 0 Aperçu
-
Global BRAF Kinase Inhibitors Market to Reach USD 3.78 Billion by 2034 Amid Rising Precision Oncology AdoptionAccording to a new report from Intel Market Research, the global BRAF kinase inhibitors market was valued at USD 1.85 billion in 2025 and is projected to reach USD 3.78 billion by 2034, growing at a CAGR of 7.5% during the forecast period (2026–2034). This growth trajectory reflects the expanding applications of BRAF inhibitors in precision oncology and the increasing prevalence of...0 Commentaires 0 Parts 643 Vue 0 Aperçu
-
Immunotherapy Impact on the Anti-cancer Drugs MarketThe rapid growth of the biotechnology sector is supporting breakthroughs in anti-cancer drug development. Researchers are leveraging advanced technologies such as gene therapy and cell-based therapies. These innovations are opening new possibilities in cancer treatment. The Anti-cancer Drugs Market is anticipated to expand at a CAGR of 9.2% from 2026 to 2034, reflecting steady innovation and...0 Commentaires 0 Parts 2KB Vue 0 Aperçu
-
VEGF Inhibitors for Cancer Market Growing at 7.3% CAGR Amid Rising Targeted Oncology TherapiesAccording to a new report from Intel Market Research, the global VEGF Inhibitors for Cancer market was valued at USD 8.42 billion in 2025 and is projected to reach USD 15.67 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2026–2034). This growth trajectory reflects the increasing adoption of targeted therapies in oncology and significant advancements in angiogenesis...0 Commentaires 0 Parts 1KB Vue 0 Aperçu